| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54868-5427-03 | 54868-5427 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 9, 2005 | Jun 30, 2013 | No Longer Used | |
| 72730-0506-01 | 72730-0506 | infigratinib | TRUSELTIQ | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | May 28, 2021 | In Use | |
| 50268-0763-12 | 50268-0763 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 23, 2017 | Jul 31, 2021 | In Use |
| 47781-0592-29 | 47781-0592 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jul 31, 2017 | Dec 1, 2019 | No Longer Used |
| 00703-4852-91 | 00703-4852 | Fludarabine phosphate | Fludarabine phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | May 1, 2004 | Sep 30, 2011 | No Longer Used |
| 72485-0214-01 | 72485-0214 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 15, 2020 | In Use | |
| 63323-0825-20 | 63323-0825 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 2, 2019 | In Use | |
| 72237-0101-06 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jun 22, 2020 | In Use | |
| 59676-0050-28 | 59676-0050 | Erdafitinib | BALVERSA | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Oral | Apr 12, 2019 | In Use | |
| 42388-0024-37 | 42388-0024 | Cabozantinib | CABOMETYX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Feb 27, 2019 | In Use | |
| 54868-5260-00 | 54868-5260 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jun 28, 2005 | In Use | |
| 31722-0412-31 | 31722-0412 | TEMOZOLOMIDE | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 23, 2024 | In Use | |
| 00069-0145-01 | 00069-0145 | Axitinib | Inlyta | 1.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 27, 2012 | In Use | |
| 51991-0991-77 | 51991-0991 | Everolimus | Everolimus | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jul 31, 2025 | In Use | |
| 59923-0708-14 | 59923-0708 | temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan 25, 2019 | In Use | |
| 72603-0408-01 | 72603-0408 | Paclitaxel | Paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 10, 2025 | In Use | |
| 60505-3802-02 | 60505-3802 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 23, 2025 | In Use | |
| 57894-0225-99 | 57894-0225 | Gemcitabine intravesical | INLEXZO | 225.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravesical | Sep 14, 2025 | In Use | |
| 40051-0605-13 | 40051-0605 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 59572-0720-12 | 59572-0720 | Fedratinib Hydrochloride | Inrebic | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Oral | Aug 16, 2019 | In Use | |
| 43598-0142-06 | 43598-0142 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan 9, 2023 | In Use | |
| 10885-0001-01 | 10885-0001 | Daunorubicin | DaunoXome | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb 13, 2012 | Apr 16, 2016 | No Longer Used | |
| 43598-0604-30 | 43598-0604 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 00781-2695-75 | 00781-2695 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
| 50742-0484-01 | 50742-0484 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use |
Found 11888 results — Export these results
Home